Odyssey Therapeutics Inc. (ODTX) carries a Roarable Rating of D (Sell) with 46/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-03, Odyssey Therapeutics Inc. (NASDAQ: ODTX) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 46/100 at a spot price of $19.53 (-0.05% 1D, market cap $939.1M). Pillar breakdown: Fundamental Cash Engine 10/20, Institutional 13F & Options Flow 6/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 9/20. Across 1015 tracked Health Care issuers, ODTX ranks #328 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), ODTX carries a Roarable D (46/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, GLUE (Monte Rosa Therapeutics Inc.) holds a E grade (25/100 RQD, P/E N/A, ROIC -35.0%, cap $918.0M) and CGEM (Cullinan Therapeutics Inc.) posts a E grade (32/100 RQD, P/E N/A, ROIC -35.0%, cap $967.3M). Among the 5-stock peer group, ODTX leads on earnings multiple (N/A) while GLUE leads on capital efficiency (-35.0% ROIC).
Per ODTX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001882782), Odyssey Therapeutics Inc. generated $113.3M in revenue, $0 in net income, and $0 in free cash flow against $269.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9
SEC XBRL FY 2025 (10-K): 23.2% FCF Margin ($26.3M FCF) & 52% Gross Margin
Put hedging (50% put share) caps near-term gamma upside (-14 pts vs max)
While ODTX currently carries a cautious 46/100 (D) rating due to Whale & Options Positioning (6/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($21.55) and Max Pain ($20.51) forces dealer call-delta covering toward $30.50.
Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.40% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Odyssey Therapeutics Inc. (ODTX) slipped -0.05% to $19.53, trading at 32% of its 52-week range ($15.1 – $29.05). Stretched risk/reward at current multiples (steady margins) under elevated 10-year interest-rate pressure.
Yahoo Finance report covering Odyssey Therapeutics Inc. (ODTX) market action, institutional positioning, and fundamental catalysts.
Simply Wall St report covering Odyssey Therapeutics Inc. (ODTX) market action, institutional positioning, and fundamental catalysts.
MarketBeat report covering Odyssey Therapeutics Inc. (ODTX) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Odyssey Therapeutics Inc. (ODTX) market action, institutional positioning, and fundamental catalysts.
Quiver Quantitative report covering Odyssey Therapeutics Inc. (ODTX) market action, institutional positioning, and fundamental catalysts.
Simply Wall St report covering Odyssey Therapeutics Inc. (ODTX) market action, institutional positioning, and fundamental catalysts.
MarketBeat report covering Odyssey Therapeutics Inc. (ODTX) market action, institutional positioning, and fundamental catalysts.
Odyssey Therapeutics (NASDAQ:ODTX) presented additional data from its open-label Phase IIa trial of OD-001, an oral RIPK2 scaffolding inhibitor for moderate-to-severe ulcerative colitis, during its UEG Week 2026 investor
Odyssey Therapeutics, Inc. (ODTX) Discusses Additional Phase IIa Data for OD-001 in Ulcerative Colitis from UEG Week Presentation October 20, 2026 8:00 AM...
Correlation between clinical efficacy and changes in inflammatory biomarkers, mucosal transcriptomic signatures, and histologic disease activity strengthens the previously shown clinical proof of concept for OD-001 Favor
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on ODTX today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for ODTX. Explore sector supply chains on /butterfly.
Across 1015 tracked Health Care securities in the Roarable RQD universe, Odyssey Therapeutics Inc. (ODTX) ranks #328 by composite RQD confidence (46/100, grade D) and #363 by equity capitalization ($939.1M). Within this direct 5-issuer industry benchmark cohort, ODTX leads on earnings valuation at N/A trailing P/E, while GLUE leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. ODTX currently leads its immediate peer cohort in composite quantitative strength at 46/100 (D).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| ODTX
ACTIVE
Odyssey Therapeutics Inc. | D | 46/100 | — | — | — | -0.05% | $939.1M | Benchmark Subject |
| GLUE Monte Rosa Therapeutics Inc. | E | 25/100 | — | — | -35.0% | -1.21% | $918.0M | /glue-vs-odtx → |
| CGEM Cullinan Therapeutics Inc. | E | 32/100 | — | — | -35.0% | -0.66% | $967.3M | /cgem-vs-odtx → |
| MGTX MeiraGTx Holdings plc | E | 20/100 | — | — | -35.0% | -1.79% | $911.4M | /mgtx-vs-odtx → |
| PRME Prime Medicine Inc. | E | 30/100 | — | — | -35.0% | -5.93% | $856.1M | /prme-vs-odtx → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Odyssey Therapeutics Inc. (ODTX) reported GAAP revenue of $113.3M , GAAP net income of $0, operating cash flow of $0, and free cash flow of $0 . On the balance sheet, ODTX closed FY2025 with $269.8M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: N/A).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $113.3M | $0 | — | — | $269.8M | — |
As of 2026-11-03, Odyssey Therapeutics Inc. (NASDAQ: ODTX) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 46/100 at a spot price of $19.53 (-0.05% 1D, market cap $939.1M). Pillar breakdown: Fundamental Cash Engine 10/20, Institutional 13F & Options Flow 6/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 9/20. Across 1015 tracked Health Care issuers, ODTX ranks #328 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), ODTX carries a Roarable D (46/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, GLUE (Monte Rosa Therapeutics Inc.) holds a E grade (25/100 RQD, P/E N/A, ROIC -35.0%, cap $918.0M) and CGEM (Cullinan Therapeutics Inc.) posts a E grade (32/100 RQD, P/E N/A, ROIC -35.0%, cap $967.3M). Among the 5-stock peer group, ODTX leads on earnings multiple (N/A) while GLUE leads on capital efficiency (-35.0% ROIC).
Per ODTX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001882782), Odyssey Therapeutics Inc. generated $113.3M in revenue, $0 in net income, and $0 in free cash flow against $269.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
ODTX last traded at $19.53 (-0.05% on volume of 258,945 shares), positioning the stock -9.37% below its 50-day simple moving average ($21.55) and -0.91% below its 200-day simple moving average ($19.71). Across its 52-week range of $15.10 to $29.05, ODTX sits at the 31.8% percentile with a 14-day RSI of 48.9 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($17.09 to $21.97).
Odyssey Therapeutics Inc. (ODTX) earns a live Roarable RQD composite score of 46/100, corresponding to a D letter grade (Roarable Sell) at a spot price of $19.53 (-0.05% 1D, market capitalization $939.1M).
And profile, Odyssey Therapeutics Inc. (ODTX) is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Biological Products (No Diagnostic Substances) industry. The profile reports a market capitalization of $1.0B. Per the news wire, the company's disclosed development activity centers on OD-001 in ulcerative colitis, with Phase 2a data and presentations referenced.
In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Odyssey Therapeutics Inc. (ODTX) reported $113.3M in annual revenue and $0 in GAAP net income. Operating cash flow reached $0 and free cash flow totaled $0, backed by $269.8M in total assets against $0 in total debt.
Supply chain is "NONE" and butterfly links are empty, so upstream and downstream dependencies cannot be mapped from source data. Sector correlation is limited to the Health Care / Biological Products classification and beta of 1.0. Second-order bottlenecks to watch are not identifiable from the provided sources; clinical-readout timing tied to the OD-001 program is the principal catalyst thread in the news wire.
Real-time company headlines, analyst actions, and sector developments for Odyssey Therapeutics Inc. (ODTX) • Click "Debate This Headline" to argue it in the Roar Pit below
Yahoo Finance report covering Odyssey Therapeutics Inc. (ODTX) market action, institutional positioning, and fundamental catalysts.
Simply Wall St report covering Odyssey Therapeutics Inc. (ODTX) market action, institutional positioning, and fundamental catalysts.
MarketBeat report covering Odyssey Therapeutics Inc. (ODTX) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Odyssey Therapeutics Inc. (ODTX) market action, institutional positioning, and fundamental catalysts.
Quiver Quantitative report covering Odyssey Therapeutics Inc. (ODTX) market action, institutional positioning, and fundamental catalysts.
Simply Wall St report covering Odyssey Therapeutics Inc. (ODTX) market action, institutional positioning, and fundamental catalysts.
MarketBeat report covering Odyssey Therapeutics Inc. (ODTX) market action, institutional positioning, and fundamental catalysts.
Odyssey Therapeutics (NASDAQ:ODTX) presented additional data from its open-label Phase IIa trial of OD-001, an oral RIPK2 scaffolding inhibitor for moderate-to-severe ulcerative colitis, during its UEG Week 2026 investor
Picked up a starter position in ODTX in my $100K Virtual Cash book at $19.54. The balance sheet scores 13/20 on Altman Z 2.5, Piotroski F 6/9 and Debt/Equity 0.5, and the news wire flags continued positive OD-001 Phase 2a ulcerative colitis data.. Trading inside a $15.10–$29.05 52-week range with 0.0% FCF yield gives solid downside support if Biotechnology: Biological Products (No Diagnostic Substances) multiples expand this quarter.
@RedlineAuditor Shorting a 6/20 institutional whale-flow stock at $19.54 is dangerous when funds are rotating into Health Care.
Fading this rally in ODTX at $19.54. Revenue, operating income, net income, ROIC and FCF yield are all reported at zero, leaving the cash-engine pillar at 10/20.. With a beta of 1.0 and the stock sitting at $19.54 (52-wk range $15.10–$29.05), the easy multiple expansion is already priced in.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Gideon Ashmere, Ellis Vennor, Tessa Rookmere, Soren Halewick, Iona Brackenford, Nadia Vellacrest, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your first name and email address below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).
Your $100,000 Virtual Cash Trading Account is active! Add your mobile number below if you want our #1 Weekly Quant Top Pick plus urgent breaking market alerts & SEC Form 4 CEO cluster-buy flashes sent straight to your phone: